Alcobra Ltd. (Nasdaq: ADHD) reported disappointing results from a Phase 2 clinical trial MDX to treat Fragile X Syndrome sending the stock price tumbling $1.09 to close at $7.30.
Alcobra reports disappointing results
June 24, 2015 at 17:15 PM EDT
